Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Focused Ultrasound With Low-Dose Gemcitabine to Augment Immune Control of Early Stage Breast Cancer

NCT04796220 is registered in ClinicalTrials.gov with Patrick Dillon, MD as lead sponsor.

NCT NCT04796220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04796220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Focused Ultrasound With Low-Dose Gemcitabine to Augment Immune Control of Early Stage Breast Cancer
Lead sponsor
Patrick Dillon, MD
Phase
Phase 1
Overall status
Active, not recruiting
Start date
January 27, 2022
Completion date
February 28, 2030
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast neoplasms